R Luke Wiseman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2053897/publications.pdf

Version: 2024-02-01

84	7,249	71102	62596
papers	citations	41 h-index	80 g-index

107	107	107	7943
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pharmacologic IRE1/XBP1s activation promotes systemic adaptive remodeling in obesity. Nature Communications, 2022, 13, 608.	12.8	31
2	Cryo-EM structure of hexameric yeast Lon protease (PIM1) highlights the importance of conserved structural elements. Journal of Biological Chemistry, 2022, 298, 101694.	3.4	6
3	Stress-responsive regulation of extracellular proteostasis. Journal of Cell Biology, 2022, 221, .	5.2	20
4	Reshaping endoplasmic reticulum quality control through the unfolded protein response. Molecular Cell, 2022, 82, 1477-1491.	9.7	105
5	Pharmacological activation of ATF6 remodels the proteostasis network to rescue pathogenic GABAA receptors. Cell and Bioscience, 2022, 12, 48.	4.8	14
6	ATF6 Activation Reduces Amyloidogenic Transthyretin Secretion through Increased Interactions with Endoplasmic Reticulum Proteostasis Factors. Cells, 2022, 11, 1661.	4.1	4
7	Pharmacologic targeting of plasma cell endoplasmic reticulum proteostasis to reduce amyloidogenic light chain secretion. Blood Advances, 2021, 5, 1037-1049.	5.2	19
8	Structures of the human LONP1 protease reveal regulatory steps involved in protease activation. Nature Communications, 2021, 12, 3239.	12.8	40
9	The 2021 FASEB Virtual Catalyst Conference on Extracellular and Organismal Proteostasis in Health and Disease, February 3â€4, 2021. FASEB Journal, 2021, 35, e21631.	0.5	1
10	Enforced dimerization between XBP1s and ATF6f enhances the protective effects of the UPR in models of neurodegeneration. Molecular Therapy, 2021, 29, 1862-1882.	8.2	25
11	ATF6 is essential for human cone photoreceptor development. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	31
12	Metabolically Activated Proteostasis Regulators Protect against Glutamate Toxicity by Activating NRF2. ACS Chemical Biology, 2021, 16, 2852-2863.	3.4	16
13	Expression of Amyloidogenic Transthyretin Drives Hepatic Proteostasis Remodeling in an Induced Pluripotent Stem Cell Model of Systemic AmyloidÂDisease. Stem Cell Reports, 2020, 15, 515-528.	4.8	12
14	Pharmacologic IRE1/XBP1s activation confers targeted ER proteostasis reprogramming. Nature Chemical Biology, 2020, 16, 1052-1061.	8.0	90
15	Defining the Functional Targets of Capâ€˜nâ€™collar Transcription Factors NRF1, NRF2, and NRF3. Antioxidants, 2020, 9, 1025.	5.1	29
16	Small molecule strategies to harness the unfolded protein response: where do we go from here?. Journal of Biological Chemistry, 2020, 295, 15692-15711.	3.4	70
17	Premature Activation of Immune Transcription Programs in Autoimmune-Predisposed Mouse Embryonic Stem Cells and Blastocysts. International Journal of Molecular Sciences, 2020, 21, 5743.	4.1	0
18	Structural basis for distinct operational modes and protease activation in AAA+ protease Lon. Science Advances, 2020, 6, eaba8404.	10.3	55

#	Article	IF	Citations
19	Insulin-like growth factor 2 (IGF2) protects against Huntingtonâ€™s disease through the extracellular disposal of protein aggregates. Acta Neuropathologica, 2020, 140, 737-764.	7.7	43
20	Starting at the beginning: endoplasmic reticulum proteostasis and systemic amyloid disease. Biochemical Journal, 2020, 477, 1721-1732.	3.7	7
21	Multiexon deletion alleles of ATF6 linked to achromatopsia. JCI Insight, 2020, 5, .	5.0	13
22	Unique Structural Features of the Mitochondrial AAA+ Protease AFG3L2 Reveal the Molecular Basis for Activity in Health and Disease. Molecular Cell, 2019, 75, 1073-1085.e6.	9.7	58
23	PERK Signaling Regulates Extracellular Proteostasis of an Amyloidogenic Protein During Endoplasmic Reticulum Stress. Scientific Reports, 2019, 9, 410.	3.3	20
24	Proteostasis and Beyond: ATF6 in Ischemic Disease. Trends in Molecular Medicine, 2019, 25, 538-550.	6.7	66
25	Non-canonical function of IRE1Î± determines mitochondria-associated endoplasmic reticulum composition to control calcium transfer and bioenergetics. Nature Cell Biology, 2019, 21, 755-767.	10.3	168
26	Quantitative Interactome Proteomics Reveals a Molecular Basis for ATF6-Dependent Regulation of a Destabilized Amyloidogenic Protein. Cell Chemical Biology, 2019, 26, 913-925.e4.	5.2	26
27	Lining up for quality control: linear ubiquitin and proteotoxicity. EMBO Journal, 2019, 38, .	7.8	0
28	Deconvoluting Stress-Responsive Proteostasis Signaling Pathways for Pharmacologic Activation Using Targeted RNA Sequencing. ACS Chemical Biology, 2019, 14, 784-795.	3.4	45
29	Pharmacologic ATF6 activation confers global protection in widespread disease models by reprograming cellular proteostasis. Nature Communications, 2019, 10, 187.	12.8	140
30	Characterization of an A-Site Selective Protein Disulfide Isomerase A1 Inhibitor. Biochemistry, 2018, 57, 2035-2043.	2.5	38
31	The unfolded protein response regulator ATF6 promotes mesodermal differentiation. Science Signaling, 2018, 11, .	3.6	54
32	The PERK Arm of the Unfolded Protein Response Regulates Mitochondrial Morphology during Acute Endoplasmic Reticulum Stress. Cell Reports, 2018, 22, 2827-2836.	6.4	172
33	Coordinating Mitochondrial Biology Through the Stress-Responsive Regulation of Mitochondrial Proteases. International Review of Cell and Molecular Biology, 2018, 340, 79-128.	3.2	17
34	A library of ATTR amyloidosis patient-specific induced pluripotent stem cells for disease modelling and in vitro testing of novel therapeutics. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 148-155.	3.0	13
35	Pharmacologic ATF6 activating compounds are metabolically activated to selectively modify endoplasmic reticulum proteins. ELife, 2018, 7, .	6.0	85
36	The Unfolded Protein Response Regulator, ATF6, Promotes Mesodermal Differentiation. FASEB Journal, 2018, 32, 542.23.	0.5	0

#	Article	IF	Citations
37	Structure of the mitochondrial inner membrane AAA+ protease YME1 gives insight into substrate processing. Science, 2017, 358, .	12.6	179
38	Regulating Secretory Proteostasis through the Unfolded Protein Response: From Function to Therapy. Trends in Cell Biology, 2017, 27, 722-737.	7.9	70
39	The endoplasmic reticulum <scp>HSP</scp>40 coâ€chaperone <scp>ER</scp>dj3/<scp>DNAJB</scp>11 assembles and functions as a tetramer. EMBO Journal, 2017, 36, 2296-2309.	7.8	38
40	Small molecule proteostasis regulators that reprogram the ER to reduce extracellular protein aggregation. ELife, 2016, 5, .	6.0	185
41	Modulating protein quality control. ELife, 2016, 5, .	6.0	12
42	Reciprocal Degradation of YME1L and OMA1 Adapts Mitochondrial Proteolytic Activity during Stress. Cell Reports, 2016, 14, 2041-2049.	6.4	132
43	Endoplasmic Reticulum Proteostasis Influences the Oligomeric State of an Amyloidogenic Protein Secreted from Mammalian Cells. Cell Chemical Biology, 2016, 23, 1282-1293.	5.2	29
44	Endoplasmic reticulum quality control and systemic amyloid disease: Impacting protein stability from the inside out. IUBMB Life, 2015, 67, 404-413.	3.4	22
45	A Fluorogenic Aryl Fluorosulfate for Intraorganellar Transthyretin Imaging in Living Cells and in Caenorhabditis elegans. Journal of the American Chemical Society, 2015, 137, 7404-7414.	13.7	86
46	<scp>YME</scp> 1L degradation reduces mitochondrial proteolytic capacity during oxidative stress. EMBO Reports, 2015, 16, 97-106.	4.5	70
47	Enhanced Aromatic Sequons Increase Oligosaccharyltransferase Glycosylation Efficiency and Glycan Homogeneity. Chemistry and Biology, 2015, 22, 1052-1062.	6.0	36
48	Regulating extracellular proteostasis capacity through the unfolded protein response. Prion, 2015, 9, 10-21.	1.8	22
49	Chaperones in Neurodegeneration. Journal of Neuroscience, 2015, 35, 13853-13859.	3.6	81
50	Targeting protein aggregation for the treatment of degenerative diseases. Nature Reviews Drug Discovery, 2015, 14, 759-780.	46.4	338
51	Unfolded protein responseâ€induced <scp>ER</scp> dj3 secretion links <scp>ER</scp> stress to extracellular proteostasis. EMBO Journal, 2015, 34, 4-19.	7.8	110
52	ATF6 Activation Reduces the Secretion and Extracellular Aggregation of Destabilized Variants of an Amyloidogenic Protein. Chemistry and Biology, 2014, 21, 1564-1574.	6.0	63
53	Unfolded protein response activation reduces secretion and extracellular aggregation of amyloidogenic immunoglobulin light chain. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13046-13051.	7.1	83
54	Stress-responsive regulation of mitochondria through the ER unfolded protein response. Trends in Endocrinology and Metabolism, 2014, 25, 528-537.	7.1	162

#	Article	IF	Citations
55	Characterizing the Altered Cellular Proteome Induced by the Stress-Independent Activation of Heat Shock Factor 1. ACS Chemical Biology, 2014, 9, 1273-1283.	3.4	51
56	Quantification of Transthyretin Kinetic Stability in Human Plasma Using Subunit Exchange. Biochemistry, 2014, 53, 1993-2006.	2.5	62
57	Stress-Independent Activation of XBP1s and/or ATF6 Reveals Three Functionally Diverse ER Proteostasis Environments. Cell Reports, 2013, 3, 1279-1292.	6.4	436
58	Induced Pluripotent Stem Cell Modeling of Multisystemic, Hereditary Transthyretin Amyloidosis. Stem Cell Reports, 2013, 1, 451-463.	4.8	42
59	Stress-Regulated Translational Attenuation Adapts Mitochondrial Protein Import through Tim17A Degradation. Cell Metabolism, 2013, 18, 908-919.	16.2	142
60	Targeting unfolded protein response signaling pathways to ameliorate protein misfolding diseases. Current Opinion in Chemical Biology, 2013, 17, 346-352.	6.1	64
61	Broadly Applicable Methodology for the Rapid and Dosable Small Molecule-Mediated Regulation of Transcription Factors in Human Cells. Journal of the American Chemical Society, 2013, 135, 8129-8132.	13.7	42
62	Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9629-9634.	7.1	582
63	Chemically Targeting the Emergent Properties of a Chaperone Complex. Chemistry and Biology, 2011, 18, 144-145.	6.0	1
64	Phosphatase Inhibition Delays Translational Recovery. Science, 2011, 332, 44-45.	12.6	42
65	Flavonol Activation Defines an Unanticipated Ligand-Binding Site in the Kinase-RNase Domain of IRE1. Molecular Cell, 2010, 38, 291-304.	9.7	173
66	SnapShot: The Unfolded Protein Response. Cell, 2010, 140, 590-590.e2.	28.9	41
67	Thioredoxin-related Protein 32 Is an Arsenite-regulated Thiol Reductase of the Proteasome 19 S Particle. Journal of Biological Chemistry, 2009, 284, 15233-15245.	3.4	38
68	Evolving Protein Stability through Genetic Selection. Molecular Cell, 2009, 36, 730-731.	9.7	2
69	An Adaptable Standard for Protein Export from the Endoplasmic Reticulum. Cell, 2007, 131, 809-821.	28.9	147
70	Protein energetics in maturation of the early secretory pathway. Current Opinion in Cell Biology, 2007, 19, 359-367.	5.4	27
71	R104H may suppress transthyretin amyloidogenesis by thermodynamic stabilization, but not by the kinetic mechanism characterizing T119 interallelic trans-suppression. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2006, 13, 57-66.	3.0	22
72	The Pathway by Which the Tetrameric Protein Transthyretin Dissociatesâ€. Biochemistry, 2005, 44, 15525-15533.	2.5	149

#	Article	IF	Citations
73	Kinetic Stabilization of an Oligomeric Protein by a Single Ligand Binding Event. Journal of the American Chemical Society, 2005, 127, 5540-5551.	13.7	95
74	Partitioning Conformational Intermediates between Competing Refolding and Aggregation Pathways:Â Insights into Transthyretin Amyloid Diseaseâ€. Biochemistry, 2005, 44, 16612-16623.	2.5	53
75	Kinetic Stabilization of an Oligomeric Protein under Physiological Conditions Demonstrated by a Lack of Subunit Exchange:â€‰ Implications for Transthyretin Amyloidosis. Biochemistry, 2005, 44, 9265-9274.	2.5	58
76	Native State Kinetic Stabilization as a Strategy To Ameliorate Protein Misfolding Diseases:Â A Focus on the Transthyretin Amyloidoses. Accounts of Chemical Research, 2005, 38, 911-921.	15.6	261
77	Kinetic Stabilization of the Native State by Protein Engineering: Implications for Inhibition of Transthyretin Amyloidogenesis. Journal of Molecular Biology, 2005, 347, 841-854.	4.2	73
78	A new pharmacology â€“ drugging stressed folding pathways. Trends in Molecular Medicine, 2005, 11, 347-350.	6.7	65
79	The Biological and Chemical Basis for Tissue-Selective Amyloid Disease. Cell, 2005, 121, 73-85.	28.9	427
80	Title is missing!. Angewandte Chemie, 2003, 115, 2864-2867.	2.0	38
81	Benzoxazoles as Transthyretin Amyloid Fibril Inhibitors: Synthesis, Evaluation, and Mechanism of Action. Angewandte Chemie - International Edition, 2003, 42, 2758-2761.	13.8	204
82	D18G Transthyretin Is Monomeric, Aggregation Prone, and Not Detectable in Plasma and Cerebrospinal Fluid:Â A Prescription for Central Nervous System Amyloidosis?â€. Biochemistry, 2003, 42, 6656-6663.	2.5	117
83	Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics. Science, 2003, 299, 713-716.	12.6	491
84	Proteostasis Modulation Prevents Photoreceptor Pathology in Retinal Organoids. SSRN Electronic Journal, 0, , .	0.4	1